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SUMMARY
What is known and objective: Monitoring and intervention for
metabolic abnormalities secondary to second-generation antipsy-
chotics (SGAs) remain weak areas of performance in mental
health care. This study evaluated the sustained impact of a
computerized physician order entry (CPOE) pop-up alert
designed to improve rates of laboratory metabolic monitoring
of patients treated with SGAs in an inpatient psychiatry unit.
Interventions carried out by the psychiatry team to manage
metabolic abnormalities found on screening were also identified.
Methods: A retrospective chart review of patients treated with
scheduled SGAs at a largeMidwestern academicmedical centre’s
inpatient adult psychiatry unit was conducted nearly 4 years after
the initial implementation of a pop-up alert. Rates of laboratory
monitoring (blood glucose level, haemoglobin A1C [HbA1c],
lipid panel) were compared to those following the initial
implementation. Medical charts of patients with abnormal
laboratory results were also reviewed to summarize interventions
made by the psychiatry team to manage identified abnormalities.
Results and discussion: Patient demographics in the current
study population (n = 129) were similar to those in the initial test
cohort (n = 157). There was no significant decrease in monitoring
of glucose levels and lipid panels (fasting or random). Nine
patients with abnormally elevated laboratories were identified.
Interventions by the psychiatry team included referrals to
appropriate healthcare professionals and initiation of
medication.
What is new and conclusions: The rate of metabolic monitoring
for inpatients on SGA therapy did not significantly change over
time with the continued use of the CPOE pop-up alert. Optimal
monitoring utilizing a CPOE pop-up alert may allow the
psychiatry team, including psychiatric pharmacists, to better
manage metabolic conditions.
WHAT IS KNOWN AND OBJECTIVE
In response to emerging evidence supporting an association
between second-generation antipsychotics (SGAs) and adverse
metabolic effects, a consensus statement of guidelines was devel-
oped and promulgated by the American Diabetes Association,
American Psychiatric Association, American Association of Clin-
ical Endocrinologists and the North American Association for the
Study of Obesity in 2004.1 The panel recommended that physicians
screen and regularly monitor patients on SGAs for weight gain, the
development of type II diabetes, and dyslipidemia.1,2 Moreover,
the guidelines recommended that when metabolic abnormalities
such as elevated fasting glucose levels were identified through
monitoring, treatment should be initiated and patients referred to
appropriate healthcare providers for follow-up care.1 Compliance
with these recommendations has been based on two assumptions:
one, that these screening measures would be implemented into
psychiatrists’ daily routine by virtue of greater awareness of the
metabolic complications of SGAs; and two, that abnormal screen-
ing would lead to further management of these metabolic
derangements, either by the psychiatrists themselves or through
expedited referrals to primary care providers (PCPs).1
Despite increased awareness and general acceptance of these
guidelines, appropriate metabolic monitoring has remained
uncommon. In fact, several studies concluded that the publication
of these guidelines in 2004 did not increase metabolic testing in
patients initiating SGA therapy.3–5 One reason for this may be the
uncertainty regarding the role of psychiatrists in directly managing
metabolic abnormalities themselves. One study by Newcomer
et al.6 found that approximately half of the psychiatrists surveyed
agreed that general healthcare management was outside of their
scope of practice, with nearly three-quarters of these respondents
stating they would seek consultation for management of adverse
metabolic effects. A 2013 study by Parameswaran et al.7 found that
psychiatrists recognized the importance of screening for metabolic
risk in patients receiving antipsychotic medications; but the
majority of these psychiatrists believed their role was limited to
metabolic screening for their patients, and that prescribing oral
medications for these abnormalities remained outside of their role.
In contrast, another study by Mangurian et al.8 found that 42%
of PCPs believed that psychiatrists have the responsibility to treat
such abnormalities with prescription medications. These conflict-
ing viewpoints about which healthcare providers are responsible
for the treatment of metabolic abnormalities associated with SGAs
pose barriers to appropriate monitoring and follow-up. Therefore,
due to low rates of metabolic monitoring and presumed lack of
interventions by psychiatrists (e.g. starting a statin, switching
antipsychotic class, referral to internal medicine), metabolic
abnormalities and cardiovascular disease are often underdiag-
nosed and undertreated in patients with serious mental illnesses.2
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In response to the suboptimal metabolic monitoring of patients
on SGAs, a study conducted by DelMonte et al.4 evaluated the
efficacy of a computerized physician order entry (CPOE) pop-up
alert designed to improve rates of laboratory metabolic monitoring
of patients treated with SGAs at a large Midwestern academic
medical centre’s inpatient psychiatry unit. Implementation of this
computerized pop-up alert led to a statistically significant
improvement in the rate of ordering fasting blood glucose levels
(468% vs. 70%) and fasting (187% vs. 599%) and non-fasting
(287% vs. 745%) lipid panels for inpatients treated with SGAs.
The study did not address whether the increased rate of monitor-
ing was sustained over time or whether abnormalities found on
screening were managed by the psychiatry team.
The purpose of our follow-up study was twofold: first, to
determine whether the rates of metabolic monitoring at a major
academic medical centre inpatient psychiatry unit have been
maintained approximately 4 years after the implementation of the
CPOE pop-up alert; and second, to determine whether abnormal-
ities found on screening were addressed by the psychiatry team.
METHODS
A retrospective chart review was conducted to compare metabolic
monitoring rates for patients admitted to a large Midwestern
academic medical centre’s inpatient psychiatry unit between 1
January 2013 and 30 June 2013 (‘current study population’ most
proximate to initiation of this study) to the monitoring rates for
patients admitted between 3 December 2008 and 3 June 2009 after
the pop-up alert was first introduced (‘original post-alert study
population’, reported in the original DelMonte et al. study).4 The
inclusion and exclusion criteria and general patient demographics
for the adult inpatient psychiatry unit for this follow-up study
have been previously published.4 All adult inpatients ages
18 years or older who were on a scheduled SGA during their
admission were included. The term ‘scheduled SGA’ was defined
as receiving at least two separate doses of an SGA and excluded
any SGAs that were given on an ‘as needed’ (PRN) basis. If a
patient was admitted multiple times during the study period, only
the first admission was included in the study. For all study
participants, patient demographics and the date and time of SGA
orders, glucose levels and lipid panels were collected from the
electronic medical records. This study was approved by the
University of Michigan Health System Institutional Review Board.
The primary outcome of this study was the rate of metabolic
monitoring, measured by the number of patients on SGAs with
fasting glucose levels and/or haemoglobin A1C (HbA1c) (both
referred to as ‘glucose levels’ for the purposes of this report), and
lipid panels available. Any glucose level and lipid panel that was
accessible to the inpatient team and collected from 12 weeks prior
to admission to the discharge date were considered as ‘baseline’
laboratories available to inpatient providers for review and
medical decision-making. This 12-week window was chosen to
align with monitoring recommended for SGAs in the consensus
statement.1 Fasting was defined as a level drawn before 9 AM,
which was the start of breakfast on the inpatient psychiatry unit
and deemed reasonable by the study authors for any laboratories
obtained within 12 weeks prior to admission.
This study also investigated how the psychiatry team managed
metabolic abnormalities in patients identified through monitoring.
From the current study population, the medical charts of patients
with ‘abnormal values’ deemed as values of fasting LDL >190 mg/
dL or triglyceride level >500 mg/dL and non-diabetic patients
with a fasting glucose level >126 mg/dL or HbA1c ≥7% were
reviewed to identify any interventions the psychiatry team carried
out to manage these metabolic abnormalities.
To analyse the results, chi-square and student’s t-tests were
conducted using SPSS to determine whether monitoring rates and
patient demographics between the current study population and
original post-alert study population were significantly different. A
two-sided P-value of <005 was considered statistically significant.
The interventions made by the psychiatry team to manage
metabolic abnormalities were not analysed using statistical tests,
but instead reviewed and described through a case series format.
RESULTS AND DISCUSSION
Patient demographics
Comparison of demographics between the two patient popula-
tions is summarized in Table 1. The only statistically significant
differences between these groups were the prevalence of coronary
artery disease/cardiovascular disease and the percentage of
patients with a discharge diagnosis of substance-related disorder,
both of which were significantly higher in the current study
population. There were no significant differences in all other
comorbidities or discharge diagnoses, age, length of stay, race, sex
and SGA agents ordered between the two populations. In addition
to the SGA agents listed in Table 1 (aripiprazole, clozapine,
olanzapine and ziprasidone), patients were also prescribed ase-
napine, paliperidone, quetiapine and risperidone during their
admissions.
Metabolic monitoring
Comparisons are summarized in Table 2. The number of patients
with glucose levels, lipid panels and both laboratories available
was not significantly different between the current study popula-
tion and original post-alert study population. The same held true
when comparing only fasting laboratories. There was a trend for
the current study population to have a higher overall rate of
monitoring fasting lipid panels. Of note, the fraction (or percent-
age) of all glucose levels and lipid panels ordered with or within
24 h of the SGA order was significantly lower for the current study
population. Also, of the 91 patients with lipid panels available, the
majority (85 patients or 93%) had these laboratories drawn during
their admission vs. in the 12 weeks prior to admission. Moreover,
all 129 patients had glucose levels available, with 95% (or 123
patients) of the laboratories drawn during admission.
Interventions by psychiatry team
Of the 129 patients treated with SGAs, nine patients had at least
one fasting glucose level or fasting lipid panel value that was
abnormally elevated. Specifically, three patients had a triglyceride
level >500 mg/dL, one patient had a fasting LDL >190 mg/dL
and five non-diabetic patients had a fasting glucose level
>126 mg/dL or HbA1c ≥7%.
DISCUSSION
There was no statistically significant difference in metabolic
monitoring rates between the current study population and the
original post-alert study population. This indicates a reasonable
likelihood that the overall rates of monitoring in this inpatient
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setting were maintained for a 4-year period, between 2009 and
2013, as the implementation of the CPOE pop-up alert. Although
metabolic monitoring rates did not decrease between the two
study populations over time, appropriate monitoring of glucose
levels and lipid panels remained less than 100% (optimal moni-
toring), as only about half of all patients who were admitted to the
inpatient psychiatry unit and treated with scheduled SGAs had
both fasting glucose levels and lipid panels available for monitor-
ing during their stay. Specifically, similar to the original post-alert
study population 4 years ago, 71% of patients had both a glucose
level and lipid panel available, but only 51% had both laboratories
drawn fasting.
Notably, the current study revealed a statistically significant
decline in the number of glucose levels or lipid panels ordered
with or within 24 h of the SGA order. This was not related to an
increase in outpatient monitoring. As described in the results, the
majority of patients had their laboratories drawn during their
admission rather than in the 12 weeks prior to admission. Instead,
this could indicate a decline in the effectiveness of the alert to
trigger ordering of these laboratory parameters. The potential
confounder of having a psychiatric pharmacist provides verbal
reminders to prescribers (physicians or nurse practitioners) on the
unit was consistent during both study periods, and this, as well as
other study limitations have previously been described.4 In all,
whereas the results of the study supported the long-term impact of
the pop-up alert in maintaining the rates of monitoring, additional
steps are still needed to increase the percentage of inpatients who
have fasting glucose levels and lipid panels available while
receiving SGAs. As in our previous study, the limitations inherent
in our design include the retrospective non-randomized study
population, the focus on only two of the multiple parameters of the
metabolic syndrome, and the difficulties in securing adequate
post-discharge data. However, this follow-up study was able to
address the ‘alert fatigue’ issue that was alluded to in the previous
article’s discussion section.
This study also included a review of the management of
identified metabolic consequences of SGAs initiated by psychi-
atrists and the continued care through collaboration with other
healthcare providers, including nurse practitioners, psychiatry
residents and a board certified psychiatric pharmacist. During
the 6-month study period, only nine patients with metabolic
abnormalities were identified. This small number limits our
ability to generalize about the management of metabolic
abnormalities by the inpatient team. Nonetheless, the medical
charts of a total of nine patients with abnormal laboratory
values exceeding the thresholds cited above were reviewed by
the authors. Upon review, it was determined that all abnormal
values were addressed appropriately (e.g. initiation of medica-
tion therapy, referral to primary care) by a psychiatry team
member. All five cases of abnormal fasting glucose levels were
addressed by psychiatrists and did not require any intervention.
Point-of-care glucose levels continued to be monitored during
admission to detect sustained elevated levels, but these patients’
abnormally elevated glucose levels returned to normal and did
not require interventions such as initiation of medication
therapy. In addition, all three cases of elevated triglyceride
levels and the one case of elevated LDL level were addressed.
To provide additional texture and context to the interventions
recommended, we briefly summarize three case reports illus-
trating the various steps taken by the psychiatry team to
manage elevated fasting lipid panels identified in the current
study.
Case 1: A 26-year-old transfemale with a history of bipolar I
disorder and elevated triglycerides was admitted to the inpa-
tient psychiatry unit for erratic behaviour secondary to mania
and psychosis. The patient was initially treated with olanzapine
as needed for severe agitation. Risperidone was then started on
a scheduled basis to manage her manic symptoms and was
continued for the remainder of her hospital stay. Upon
discharge 1 week later, a baseline fasting lipid panel was drawn
and the patient’s triglyceride level was found to be 1130 mg/
dL. The patient’s discharge medication regimen included
Table 1. Patient demographics of current study population com-








(n = 157) P-value
Average age (years  SDb) 41  19 42  15 0619
Length of stay (days  SDb) 161  143 134  135 0102
Comorbidities
Diabetes 17 (132) 20 (127) 0912
Hyperlipidaemia 25 (194) 20 (127) 0125
CAD/CVDc 14 (109) 4 (25) 0004
BMI >25 or diagnosis
‘obesity’
8 (62) 9 (57) 0867
Patients w/≥1 of
the above
46 (357) 41 (261) 0081
Race
Caucasian 104 (806) 126 (803) 0938
Black/African American 15 (116) 16 (102) 0679
Hispanic 0 (-) 3 (19) 0114
Native American 0 (-) 0 (-) –
Bi/Multiracial 0 (-) 1 (06) 0364
Asian 3 (23) 3 (19) 0808
Middle Eastern 0 (-) 2 (13) 0198
Unknown/Other 3 (23) 2 (13) 0500
Not listed 4 (31) 4 (26) 0778
Sex
Male 70 (543) 77 (490) 0380




47 (364) 44 (280) 0129
Depressive disorders 34 (264) 47 (299) 0504
Bipolar disorders 21 (163) 39 (248) 0077
Mood disorders NOS 10 (78) 11 (70) 0810
Personality disorders 4 (31) 4 (25) 0778
Dementia 1 (08) 2 (13) 0680
Anxiety disorders 6 (47) 6 (38) 0728
Substance-related disorder 4 (31) 0 (-) 0026
Adjustment disorder 0 (-) 1 (06) 0364




36 (279) 35 (223) 0274
Aripiprazole/Ziprasidone
(low risk)
33 (256) 37 (236) 0693
Data presented as n (%) unless otherwise specified.
aOriginal post-alert study population as reported by DelMonte et al.4
bSD, Standard deviation.
cCAD/CVD, Coronary artery disease/cardiovascular disease.
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risperidone and lithium carbonate but no medications for
hyperlipidemia. The patient was directed to follow up with an
endocrinologist or her PCP to manage the elevated triglyceride
levels. Post-discharge, as an outpatient outside of our health
system, risperidone was replaced with a combination of
paliperidone and bupropion for unspecified reasons. The
patient also attended nutrition counselling appointments, where
she received recommendations on healthy diet and lifestyle
changes. Despite this education and subsequent weight loss, the
patient continued to have elevated triglyceride levels. It was not
until a follow-up PCP appointment approximately 5 months
following her discharge from the inpatient unit that the patient
was prescribed gemfibrozil and referred to a cardiology/lipid
clinic. The patient was also prescribed omega-3 fatty acids – fish
oil. In reference to the elevated triglyceride levels, the PCP’s
documentation was that the ‘timing suggests some contribution
from lithium and/or paliperidone, but may have familial
component as well.’
Case 2: A 29-year-old male was admitted to the inpatient
psychiatry unit for an acute schizophrenia exacerbation, possi-
bly due to medication non-adherence. During his stay, the
patient was initially prescribed asenapine for acute manage-
ment. This was followed by paliperidone, prior to transitioning
to paliperidone palmitate long-acting injection. Initiation of the
antipsychotic regimen led to symptom improvement and was
well-tolerated. A lipid panel was drawn 4 days into his
inpatient stay and revealed an elevated triglyceride level of
1373 mg/dL and a total cholesterol level of 364 mg/dL.
However, because it was drawn shortly after 9 AM, the result
may not have been a true fasting level. The patient was started
on simvastatin the following day and upon discharge was
instructed to continue simvastatin. Two months after discharge,
the patient remained on a statin, according to medical records,
although it had been changed to pravastatin at an outpatient
family medicine visit.
Case 3: A 29-year-old male with a history of schizophrenia was
admitted to the inpatient psychiatry unit for worsening
psychosis and poor oral intake. In the month prior to his
admission, the patient had several medication changes. First, the
patient had been switched from risperidone to olanzapine due
to negative symptoms and extrapyramidal symptoms. The
patient was subsequently switched to aripiprazole due to
metabolic concerns. Of note, the patient had not been taking
aripiprazole for at least 5 days before his admission. During his
stay, the patient was started on paliperidone and transitioned to
paliperidone palmitate long-acting injections. When a fasting
lipid panel drawn during the hospitalization revealed an LDL
level of 245 mg/dL, the patient was started on simvastatin. At
discharge, the patient was instructed to continue taking
simvastatin and to follow up with his PCP for further manage-
ment of hyperlipidemia.
These case studies illustrate the different ways inpatient
psychiatrists initiated management of metabolic abnormalities
that were identified through monitoring. Interventions included
referrals to appropriate healthcare providers and prescribing
medications, such as statins to target elevated lipids. Laboratory
abnormalities were generally managed following consultation
with an internist or the clinical pharmacist on the unit. With
increased monitoring of metabolic parameters as supported by
guidelines, the psychiatry team plays a critical role in the
management of hyperglycaemia and the development of type II
diabetes, dyslipidemia and obesity. If psychiatrists are able to
identify and initiate treatment of metabolic conditions secondary
to SGA therapy early on by active laboratory monitoring, the
prevalence of metabolic complications in patients with serious
mental illnesses can be reduced. This may require use of
medications outside a psychiatrist’s typical scope of practice or
collaboration with PCPs or other healthcare providers – includ-
ing clinical pharmacists – with expertise in managing these
conditions.
Table 2. Glucose and lipid monitoring ratesa
Glucose levels Current study population (n = 129) Original post-alert study population (n = 157) P-value
Patients with glucose level available 129 (100) 157 (100) –
Subset drawn fasting 87 (674) 110 (700) 0634
Patients with fasting glucose level available (overall) 87 (674) 110 (700) 0634
Level ordered with SGA 3 (23) 31 (197) <00001
Subset drawn fasting 3 (23) 23 (146) <00001
Level ordered within 24 h of SGA 30 (233) 63 (401) 0002
Subset drawn fasting 24 (186) 46 (293) 0036
Lipid panels
Patients with lipid panel available 91 (705) 117 (745) 0452
Subset drawn fasting 81 (890) 94 (810) 0090
Patients with fasting lipid panel available (overall) 81 (628) 94 (599) 0614
Panel ordered with SGA 3 (33) 38 (325) <00001
Subset drawn fasting 3 (33) 30 (256) <00001
Panel ordered within 24 h of SGA 21 (231) 57 (487) <00001
Subset drawn fasting 21 (231) 48 (410) 0006
Both (glucose and lipid)
Patients with glucose level and lipid panel available 91 (705) 117 (745) 0452
Fasting glucose level and lipid panel available 66 (512) 75 (478) 0568
Data presented as n (%) unless otherwise specified.
aOriginal post-alert study population as reported by DelMonte et al.4
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WHAT IS NEW AND CONCLUSION
At our institution, we have developed a system, in collaboration
with an interdisciplinary team including a clinical pharmacist, to
improve metabolic monitoring. With the challenges inherent in
monitoring for metabolic complications in patients receiving
antipsychotic medication, this study found that an inpatient CPOE
pop-up alert is associated with sustained monitoring of fasting
glucose levels and lipid panels for inpatients treated with
scheduled SGAs. However, overall, only about half of these
patients were appropriately monitored for metabolic abnormali-
ties. Steps must be taken to ensure that all patients who are at
increased for developing metabolic conditions due to SGAs be
monitored during admission to inpatient psychiatry units and
upon discharge. Further, it is critical that abnormal values be
adequately managed when identified, either by the psychiatry
team or by working in collaboration with primary care providers.
Through enhanced monitoring, appropriate management, and
adequate communication of abnormal findings to outpatient
providers, psychiatrists and pharmacists can play a key role in
the management of metabolic abnormalities.
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